← Back to Search

129Xe MRI for Interstitial Lung Disease

Phase 2
Recruiting
Led By Joseph Mammarappallil, MD
Research Sponsored by Bastiaan Driehuys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Subject has history of any known ventricular cardiac arrhythmia
Subject is less than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to detect disease activity in interstitial lung diseases using MRI.

Who is the study for?
This trial is for adults over 18 with Interstitial Lung Disease diagnosed by a specialist. Participants must be able to consent and follow the study plan. It's not for those with low oxygen levels, recent respiratory infections, MRI contraindications, pregnant or breastfeeding women, or individuals unable to hold their breath for 15 seconds.
What is being tested?
The study aims to perfect a noninvasive lung imaging technique using Hyperpolarized 129Xe gas exchange MRI. This method could help visualize how ILD responds to treatments across multiple centers involved in this NIH-sponsored research.
What are the potential side effects?
Since the intervention involves an MRI scan using a special gas called Hyperpolarized Xenon-129, side effects might include discomfort from holding one's breath during scanning and potential claustrophobia inside the MRI machine.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of irregular heartbeats from the lower chambers of my heart.
Select...
I am under 18 years old.
Select...
I had a cardiac arrest in the past year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Healthy VolunteersActive Control1 Intervention
Group II: Patients with Interstitial Lung DiseaseActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of CincinnatiOTHER
439 Previous Clinical Trials
638,601 Total Patients Enrolled
Children's Hospital Medical Center, CincinnatiOTHER
839 Previous Clinical Trials
6,565,456 Total Patients Enrolled
University of IowaOTHER
471 Previous Clinical Trials
894,514 Total Patients Enrolled
Bastiaan DriehuysLead Sponsor
14 Previous Clinical Trials
934 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,795,084 Total Patients Enrolled
Joseph Mammarappallil, MDPrincipal InvestigatorDuke University
1 Previous Clinical Trials
125 Total Patients Enrolled

Media Library

Healthy Volunteers Clinical Trial Eligibility Overview. Trial Name: NCT04855305 — Phase 2
Interstitial Lung Disease Research Study Groups: Healthy Volunteers, Patients with Interstitial Lung Disease
Interstitial Lung Disease Clinical Trial 2023: Healthy Volunteers Highlights & Side Effects. Trial Name: NCT04855305 — Phase 2
Healthy Volunteers 2023 Treatment Timeline for Medical Study. Trial Name: NCT04855305 — Phase 2
~11 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top